Thyroid Cancers | Clinical

November 29, 2022

Advances in thyroid cancer to date hold promise for other orphan cancers with analogous alterations, on which we might bring to bear agents that will have similar effects.

November 21, 2022

Larisa Greenberg, MD, discusses how the treatment landscape for metastatic thyroid cancer has moved forward in recent years.

November 20, 2022

In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions

November 16, 2022

Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.

November 16, 2022

Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.

November 16, 2022

A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.

November 16, 2022

Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.

November 16, 2022

Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.

November 16, 2022

Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.

November 02, 2022

In an interview with Targeted Oncology, Jennifer Hong Kuo, MD, discussed the use of radiofrequency ablation to treat thyroid nodules and how research from Columbia University will guide further research around this topic